title: Phase II multicenter study of arsenic trioxide, ascorbic acid and dexamethasone in patients with relapsed or refractory multiple myeloma.
abstract: Arsenic trioxide induces growth inhibition and apoptosis in multiple myeloma cell lines. Reducing glutathione by ascorbic acid may enhance the efficacy of arsenic trioxide. Here we report the results of an international multi-center study of arsenic trioxide in combination with ascorbic acid and dexamethasone as treatment for patients with advanced multiple myeloma.
authors.forename: Ka Lung
authors.initials: KL
authors.lastname: Wu
authors.forename: Meral
authors.initials: M
authors.lastname: Beksac
authors.forename: Jan
authors.initials: J
authors.lastname: van Droogenbroeck
authors.forename: Sergio
authors.initials: S
authors.lastname: Amadori
authors.forename: Sonja
authors.initials: S
authors.lastname: Zweegman
authors.forename: Pieter
authors.initials: P
authors.lastname: Sonneveld
mesh_terms: D000328:Adult; D000368:Aged; D000077237:Arsenic Trioxide; D001152:Arsenicals / Q000008:administration & dosage*; D001205:Ascorbic Acid / Q000008:administration & dosage*; D003907:Dexamethasone / Q000008:administration & dosage*; D004359:Drug Therapy, Combination; D005500:Follow-Up Studies; D006801:Humans; D008875:Middle Aged; D009101:Multiple Myeloma / Q000188:drug therapy* / Q000401:mortality; D010087:Oxides / Q000008:administration & dosage*; D012008:Recurrence
chemical_list: D001152:Arsenicals; D010087:Oxides; D003907:Dexamethasone; D001205:Ascorbic Acid; D000077237:Arsenic Trioxide